The biotech company Evotec is further expanding its biologics activities: At the French site in Toulouse, construction work on a large J.POD biologics plant has now officially started. This will be the second facility of its kind, alongside Evotec’s J.POD facility in the US. The construction is being funded by the French government.
According to Evotec, the plant should be able to significantly reduce both the scaling risks and the production costs for biologics. The new building should go into operation in the second half of 2024 and offer more than 150 new jobs, the Hamburg-based company has announced.
„We are convinced that the disruptive J.POD technology has the potential to provide biologics with the best possible quality and at the lowest possible cost,” said Craig Johnstone, Chief Operating Officer of Evotec (WKN: 566480, ISIN: DE0005664809, Chart ) . .